LENSAR, Inc.

NASDAQ:LNSR

Medical - Devices

Healthcare
$4.85 -8.15%

-$0.51 today

Market cap
$59.63M
Beta
0.87
P/E (TTM)
2.4
EPS (TTM)
$2.42
52W Low $5.06High $13.47

Volume 0.06M

Average 0.09M

LNSR Pre-Tax Margin

Income before tax as a percentage of revenue.

LENSAR, Inc.NASDAQ: LNSR

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to 270.6%

Pre-tax margin was 270.6% in Q1 FY2026, up 463.7 pp from a year earlier. On a trailing-twelve-month basis it was 50.9%, up 150.1 pp year over year. Over 3 fiscal years it narrowed by 2.3 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
270.6%+279.7 pp QoQ
Last fiscal yearDec 2025
-58.7%+0.0 pp YoY
LTMMar 2026
50.9%+150.1 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+463.7 pp——
1 year+0.0 pp——
3 years-2.3 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-58.7%
Year-over-year change
+0.0pp

Pre-Tax Margin vs competitors

How LNSR compares with its peers on the latest reported figures

  • LNSR's LTM Mar 2026 pre-tax margin of 50.9% is the highest of the 9 companies compared; the peer median is -133.4%.
  • Its year-over-year change of +150.1 pp is the highest of 9, against a peer median of -7.3 pp.
  • Over three fiscal years its change of -2.3 pp compares with a peer median of +119.5 pp.
LNSR Competitors Peer median
Pre-Tax Margin for LNSR and competitors
Company Period LTM level YoY 3-year change
LNSRLENSAR, Inc.LTM Mar 202650.9% +150.1 pp-2.3 pp
ANIKAnika Therapeutics, Inc.LTM Mar 2026-8.8% -4.4 pp-12.0 pp
OWLTOwlet, Inc.LTM Mar 2026-43.0% -28.6 pp+77.1 pp
TLSITriSalus Life Sciences, Inc.LTM Mar 2026-60.8% +23.8 pp+293.7 pp
MXCTMaxCyte, Inc.LTM Mar 2026-121.2% -10.2 pp-81.9 pp
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026-145.7% +5.4 pp+218.1 pp
PROFProfound Medical Corp.LTM Mar 2026-206.5% +64.8 pp+161.9 pp
AVRAnteris Technologies Global Corp.LTM Mar 2026-5116.2% -1836.7 pp-3970.6 pp
CRDFCardiff Oncology, Inc.LTM Mar 2026-8526.1% -217.6 pp+2294.9 pp
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
Peer median (excluding LNSR) -133.4%-7.3 pp+119.5 pp

Competitors are the stored peer set for LNSR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.46M35.36M42.16M53.49M58.44M
Cost of Revenue16.63M15.4M21.06M27.64M31.31M
Gross Profit17.83M19.96M21.11M25.85M27.12M
Gross Margin51.8%56.4%50.1%48.3%46.4%
Research & Development12.36M11.81M6.14M5.33M5.62M
Selling, General & Admin23.89M27.17M26.1M26.49M45.16M
Operating Expenses37.49M40.13M33.34M36.52M51.7M
Depreciation & Amortization2.76M3.41M3.52M3.93M4.5M
EBITDA(16.84M)(16.51M)(10.87M)(3.01M)(29.78M)
EBITDA Margin-48.9%-46.7%-25.8%-5.6%-51.0%
Operating Income(19.65M)(20.18M)(12.23M)(10.67M)(24.58M)
Operating Margin-57.0%-57.1%-29.0%-19.9%-42.1%
Interest Income34K17K85K103K91K
Interest Expense00000
Other Income / Expenses51K263K(2.15M)(20.74M)(9.7M)
Income Before Tax(19.6M)(19.91M)(14.38M)(31.4M)(34.28M)
Pre-Tax Margin-56.9%-56.3%-34.1%-58.7%-58.7%
Income Tax Expense00000
Net Income(19.6M)(19.91M)(14.38M)(31.4M)(34.28M)
Net Margin-56.9%-56.3%-34.1%-58.7%-58.7%
EPS (Basic)(2.10)(1.96)(1.31)(2.73)(2.87)
EPS (Diluted)(2.10)(1.96)(1.31)(2.73)(2.87)
Weighted Avg Shares9.37M10.16M10.97M11.52M11.96M
Weighted Avg Shares (Diluted)9.37M10.16M10.97M11.52M11.96M

LENSAR, Inc.

NASDAQ:LNSR

Intrinsic Alpha fair value

Locked

Current Price

$4.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.